WO2005032276A1 - Dietetic preparation with hyaluronate for treatment of osteoporosis - Google Patents
Dietetic preparation with hyaluronate for treatment of osteoporosis Download PDFInfo
- Publication number
- WO2005032276A1 WO2005032276A1 PCT/CZ2004/000064 CZ2004000064W WO2005032276A1 WO 2005032276 A1 WO2005032276 A1 WO 2005032276A1 CZ 2004000064 W CZ2004000064 W CZ 2004000064W WO 2005032276 A1 WO2005032276 A1 WO 2005032276A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dietetic preparation
- preparation according
- salt
- osteoporosis
- dietetic
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 17
- 235000005911 diet Nutrition 0.000 title claims abstract description 17
- 230000000378 dietary effect Effects 0.000 title claims abstract description 17
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 title description 7
- 229940014041 hyaluronate Drugs 0.000 title description 7
- 235000020357 syrup Nutrition 0.000 claims abstract description 10
- 239000006188 syrup Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 8
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 8
- 230000001055 chewing effect Effects 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 229940112822 chewing gum Drugs 0.000 claims abstract description 4
- 235000015218 chewing gum Nutrition 0.000 claims abstract description 4
- 235000009508 confectionery Nutrition 0.000 claims abstract description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 3
- 244000060011 Cocos nucifera Species 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 235000008476 powdered milk Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019742 Vitamins premix Nutrition 0.000 claims description 2
- 239000008369 fruit flavor Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 235000015110 jellies Nutrition 0.000 abstract description 2
- 239000008274 jelly Substances 0.000 abstract description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 7
- 229940010747 sodium hyaluronate Drugs 0.000 description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 7
- 102000055006 Calcitonin Human genes 0.000 description 5
- 108060001064 Calcitonin Proteins 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 229960004015 calcitonin Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000005805 Prunus cerasus Nutrition 0.000 description 1
- 244000207449 Prunus puddum Species 0.000 description 1
- 235000009226 Prunus puddum Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910000514 dolomite Inorganic materials 0.000 description 1
- 239000010459 dolomite Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602004020087T DE602004020087D1 (en) | 2003-10-08 | 2004-10-08 | HYALURONIC DIET PRODUCT FOR THE TREATMENT OF OSTEOPOROSIS |
PL04762316T PL1677627T3 (en) | 2003-10-08 | 2004-10-08 | Dietetic preparation with hyaluronate for treatment of osteoporosis |
US10/575,073 US20070218030A1 (en) | 2003-10-08 | 2004-10-08 | Dietetic Preparation for Prevention and Treatment of Osteoporosis |
EP04762316A EP1677627B1 (en) | 2003-10-08 | 2004-10-08 | Dietetic preparation with hyaluronate for treatment of osteoporosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ200314679U CZ13928U1 (en) | 2003-10-08 | 2003-10-08 | Dietetic preparation for the prevention and treatment of osteoporosis |
CZPUV14679-03 | 2003-10-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005032276A1 true WO2005032276A1 (en) | 2005-04-14 |
WO2005032276B1 WO2005032276B1 (en) | 2005-06-02 |
Family
ID=31954632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2004/000064 WO2005032276A1 (en) | 2003-10-08 | 2004-10-08 | Dietetic preparation with hyaluronate for treatment of osteoporosis |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070218030A1 (en) |
EP (1) | EP1677627B1 (en) |
AT (1) | ATE425678T1 (en) |
CZ (1) | CZ13928U1 (en) |
DE (1) | DE602004020087D1 (en) |
ES (1) | ES2323643T3 (en) |
PL (1) | PL1677627T3 (en) |
WO (1) | WO2005032276A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100348621C (en) * | 2005-12-02 | 2007-11-14 | 凌沛学 | Bismuth hyalurate and its preparation method and uses |
CN100355790C (en) * | 2005-11-04 | 2007-12-19 | 山东福瑞达生物化工有限公司 | Method for preparing transparent zinc hyaluronic acid |
EP2143433A1 (en) | 2008-07-08 | 2010-01-13 | ISOline s.r.o. | Preparation for the prevention of joint disease |
WO2010121700A1 (en) | 2009-04-21 | 2010-10-28 | Fidia Farmaceutici S.P.A. | Compositions containing hyaluronic acid, sulphated hyaluronic acid, calcium and vitamin d3 for the treatment of osteoarticular and musculoskeletal disorders |
WO2010127250A1 (en) * | 2009-04-30 | 2010-11-04 | Masafumi Yamai | Chewing gum composition, chewing gum product, and method for manufacturing same |
EP2786782A1 (en) | 2006-05-31 | 2014-10-08 | FIDIA FARMACEUTICI S.p.A. | Sulphated hyaluronic acid for treating degenerative osteoarthritis |
JP6192141B1 (en) * | 2016-08-04 | 2017-09-06 | 有限会社エヌアール・ラボラトリー | Bone loss inhibitor and osteoporosis preventive or ameliorating agent containing the same as an active ingredient |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2444365C1 (en) * | 2010-12-15 | 2012-03-10 | Общество с ограниченной ответственностью "СОЗИДАТЕЛЪ" | Pharmaceutical composition myceostin stimulating supporting tissue and articular cartilage regeneration (versions) |
CN102894372A (en) * | 2012-11-05 | 2013-01-30 | 江苏江大源生态生物科技有限公司 | Health-care food for increasing bone density and preparation method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033592A1 (en) * | 1996-03-14 | 1997-09-18 | Hyal Pharmaceutical Corporation | Methods for cell mobilization using in vivo treatment with hyaluronan (ha) |
US6391864B1 (en) * | 1998-08-19 | 2002-05-21 | Joint Juice, Inc. | Food supplement containing a cartilage supplement |
US6495148B1 (en) * | 1998-08-05 | 2002-12-17 | Giuliana Abbiati | Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions |
US20030050277A1 (en) * | 2001-03-27 | 2003-03-13 | Q.P. Corporation | Oral skin improving agent, skin improving method, and food composition for improving skin |
JP2003212781A (en) * | 2002-01-22 | 2003-07-30 | Maruzen Pharmaceut Co Ltd | Hyaluronic acid production promoter, skin cosmetic and food and beverage for beautification |
WO2003099992A2 (en) * | 2002-05-17 | 2003-12-04 | Wyeth | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
JP2004137183A (en) * | 2002-10-17 | 2004-05-13 | Kotobuki Seiyaku Kk | Oral administration medicine, health food product or nutritional medicine composition containing glucosaminoglycan or its salt |
WO2004071543A1 (en) * | 2003-02-13 | 2004-08-26 | Synthes Ag Chur | Injectable bone-replacement mixture |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2247389C (en) * | 1996-12-27 | 2009-11-24 | Seikagaku Corporation | Agent for treatment of bladder troubles |
US6645948B2 (en) * | 1998-03-24 | 2003-11-11 | George D. Petito | Nutritional composition for the treatment of connective tissue |
US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
US6607745B2 (en) * | 2001-05-18 | 2003-08-19 | Harry Leneau | Ingestion of hyaluronic acid for improved joint function and health |
-
2003
- 2003-10-08 CZ CZ200314679U patent/CZ13928U1/en not_active IP Right Cessation
-
2004
- 2004-10-08 ES ES04762316T patent/ES2323643T3/en active Active
- 2004-10-08 WO PCT/CZ2004/000064 patent/WO2005032276A1/en active Application Filing
- 2004-10-08 PL PL04762316T patent/PL1677627T3/en unknown
- 2004-10-08 EP EP04762316A patent/EP1677627B1/en not_active Not-in-force
- 2004-10-08 US US10/575,073 patent/US20070218030A1/en not_active Abandoned
- 2004-10-08 DE DE602004020087T patent/DE602004020087D1/en active Active
- 2004-10-08 AT AT04762316T patent/ATE425678T1/en active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033592A1 (en) * | 1996-03-14 | 1997-09-18 | Hyal Pharmaceutical Corporation | Methods for cell mobilization using in vivo treatment with hyaluronan (ha) |
US6495148B1 (en) * | 1998-08-05 | 2002-12-17 | Giuliana Abbiati | Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions |
US6391864B1 (en) * | 1998-08-19 | 2002-05-21 | Joint Juice, Inc. | Food supplement containing a cartilage supplement |
US20030050277A1 (en) * | 2001-03-27 | 2003-03-13 | Q.P. Corporation | Oral skin improving agent, skin improving method, and food composition for improving skin |
JP2003212781A (en) * | 2002-01-22 | 2003-07-30 | Maruzen Pharmaceut Co Ltd | Hyaluronic acid production promoter, skin cosmetic and food and beverage for beautification |
WO2003099992A2 (en) * | 2002-05-17 | 2003-12-04 | Wyeth | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
JP2004137183A (en) * | 2002-10-17 | 2004-05-13 | Kotobuki Seiyaku Kk | Oral administration medicine, health food product or nutritional medicine composition containing glucosaminoglycan or its salt |
WO2004071543A1 (en) * | 2003-02-13 | 2004-08-26 | Synthes Ag Chur | Injectable bone-replacement mixture |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Section Ch Week 200375, Derwent World Patents Index; Class B04, AN 2003-793480, XP002314988 * |
DATABASE WPI Section Ch Week 200435, Derwent World Patents Index; Class B04, AN 2004-369103, XP002314986 * |
NAKAMURA KIMIHIDE ET AL: "High, but not low, molecular weight hyaluronan prevents T-cell-mediated liver injury by reducing proinflammatory cytokines in mice", JOURNAL OF GASTROENTEROLOGY, vol. 39, no. 4, April 2004 (2004-04-01), pages 346 - 354, XP008042013, ISSN: 0944-1174 * |
STANCÍKOVÁ M ET AL: "The effects of hyaluronan on bone resorption and bone mineral density in a rat model of estrogen deficiency-induced osteopenia", INTERNATIONAL JOURNAL OF TISSUE REACTIONS 2004 SWITZERLAND, vol. 26, no. 1-2, 2004, pages 9 - 16, XP008042023, ISSN: 0250-0868 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100355790C (en) * | 2005-11-04 | 2007-12-19 | 山东福瑞达生物化工有限公司 | Method for preparing transparent zinc hyaluronic acid |
CN100348621C (en) * | 2005-12-02 | 2007-11-14 | 凌沛学 | Bismuth hyalurate and its preparation method and uses |
EP2786782A1 (en) | 2006-05-31 | 2014-10-08 | FIDIA FARMACEUTICI S.p.A. | Sulphated hyaluronic acid for treating degenerative osteoarthritis |
EP2143433A1 (en) | 2008-07-08 | 2010-01-13 | ISOline s.r.o. | Preparation for the prevention of joint disease |
WO2010121700A1 (en) | 2009-04-21 | 2010-10-28 | Fidia Farmaceutici S.P.A. | Compositions containing hyaluronic acid, sulphated hyaluronic acid, calcium and vitamin d3 for the treatment of osteoarticular and musculoskeletal disorders |
WO2010127250A1 (en) * | 2009-04-30 | 2010-11-04 | Masafumi Yamai | Chewing gum composition, chewing gum product, and method for manufacturing same |
JP6192141B1 (en) * | 2016-08-04 | 2017-09-06 | 有限会社エヌアール・ラボラトリー | Bone loss inhibitor and osteoporosis preventive or ameliorating agent containing the same as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
ATE425678T1 (en) | 2009-04-15 |
EP1677627A1 (en) | 2006-07-12 |
CZ13928U1 (en) | 2004-01-20 |
US20070218030A1 (en) | 2007-09-20 |
PL1677627T3 (en) | 2009-08-31 |
WO2005032276B1 (en) | 2005-06-02 |
EP1677627B1 (en) | 2009-03-18 |
ES2323643T3 (en) | 2009-07-22 |
DE602004020087D1 (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9387168B2 (en) | Chewing gum with tomatidine | |
EP2643007B1 (en) | Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of gastroesophageal reflux disease | |
JP4423447B2 (en) | Osteoporosis preventive and therapeutic agent | |
US20140134281A1 (en) | Functional formulation | |
CN108783467B (en) | Composition for improving osteoporosis and increasing bone density and preparation method thereof | |
JPH11243910A (en) | Food composition for prevention of periodontal diseases and for prevention of advance of periodontal diseases | |
AU2006238853A1 (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
EP1677627B1 (en) | Dietetic preparation with hyaluronate for treatment of osteoporosis | |
WO2000074696A1 (en) | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe | |
EP1161944B1 (en) | Drugs, foods and oral compositions containing stilbene-type compounds | |
KR20070113460A (en) | The health food composition for regulating weight | |
JP3712732B2 (en) | Agents that act on bone formation diseases | |
JP5281895B2 (en) | Calcium absorption promoter | |
KR102225792B1 (en) | Pharmaceutical composition for the treatment or prevention of postmenopausal syndrome containing Echinochrome A | |
JP2002020278A (en) | Chewing gum for preventing cancer of oral cavity | |
JP2009209088A (en) | Muscle-enhancing agent containing asperuloside or its analog | |
JP6112767B2 (en) | Composition for lowering uric acid level in blood | |
JPH11147828A (en) | Absorption inhibitor against cholesterol and lipid | |
WO2008080809A2 (en) | Pharmaceutical composition containing psyllium and senna | |
JP2002187847A (en) | Composition for supplying calcium | |
KR20090027383A (en) | Composition for preventing or treating hyperlipidemia | |
WO2008080810A2 (en) | Composition comprising cocoa fibre | |
JP4465963B2 (en) | Composition for preventing or improving hyperlipidemia | |
CN116157114A (en) | Effervescent formulations containing apoaequorin | |
KR101059332B1 (en) | Composition for the prevention and treatment of osteoporosis disease containing mixed herbal extracts of safflower, succinate and sine as active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
B | Later publication of amended claims |
Effective date: 20050405 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004762316 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004762316 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007218030 Country of ref document: US Ref document number: 10575073 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10575073 Country of ref document: US |